Mar 31, 2013, 11.44 AM | Source: Reuters
Broader sentiment is expected to be weak in Indian stocks after data showed the current account deficit widened to a record high 6.7 percent of GDP in the October-December quarter.
However, the data, coming out after market hours on Thursday, also showed the balance of payments turned positive.
Still, traders say macro-economic indicators may have bottomed out and point to signs of recovery ahead.
Analysts also feel the recent correction in shares have made valuations more compelling.
Drug makers could be in focus as the Supreme Court is due to decide on April 1 whether Novartis AG's cancer treatment Glivec deserves a patent in the country.
KEY EVENTS/FACTORS TO WATCH:
Mon: March HSBC manufacturing PMI, Feb infrastructure output
- Supreme Court ruling on Novartis' Glivec
- Debt/FX markets closed for banking holiday
Wall Street weekahead: Is a turnaround near?
As US stocks continue to struggle in 2016, equitie
What's behind the global stock market selloff?
Global stock markets are on their shakiest footing
UAE oil minister expects market supply to 'stabilise'
"The market will oblige all (producers) not to red
Nordea Emerging Market sells 6.97 lakh shares of Just Dial
Nordea Emerging Market Equity Fund sold 697,258 sh
Uber gets another $200 mn for emerging markets push
Is this another 2008 for Indian market? Jaipuria discusses
On banks, Independent market expert Jyotivardhan J